Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development… Read more
Mabion S.A. (MAB) - Net Assets
Latest net assets as of September 2025: zł70.02 Million PLN
Based on the latest financial reports, Mabion S.A. (MAB) has net assets worth zł70.02 Million PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł120.46 Million) and total liabilities (zł50.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł70.02 Million |
| % of Total Assets | 58.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -12.69% |
| Growth Volatility | 2635.16 |
Mabion S.A. - Net Assets Trend (2009–2024)
This chart illustrates how Mabion S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mabion S.A. (2009–2024)
The table below shows the annual net assets of Mabion S.A. from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł111.44 Million | -5.38% |
| 2023-12-31 | zł117.78 Million | +53.94% |
| 2022-12-31 | zł76.51 Million | +43.51% |
| 2021-12-31 | zł53.31 Million | +168.89% |
| 2020-12-31 | zł-77.39 Million | -258.61% |
| 2019-12-31 | zł-21.58 Million | -151.21% |
| 2018-12-31 | zł42.14 Million | +177.81% |
| 2017-12-31 | zł-54.16 Million | -1552.35% |
| 2016-12-31 | zł3.73 Million | -97.08% |
| 2015-12-31 | zł127.64 Million | -87.21% |
| 2014-12-31 | zł997.84 Million | +91.69% |
| 2013-12-31 | zł520.55 Million | -71.47% |
| 2012-12-31 | zł1.82 Billion | +8858.29% |
| 2011-12-31 | zł20.37 Million | -6.23% |
| 2010-12-31 | zł21.72 Million | +29137.19% |
| 2009-12-31 | zł-74.80K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mabion S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15023420202.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł1.62 Million | 1.45% |
| Other Comprehensive Income | zł23.19 Million | 20.81% |
| Other Components | zł237.44 Million | 213.06% |
| Total Equity | zł111.44 Million | 100.00% |
Mabion S.A. Competitors by Market Cap
The table below lists competitors of Mabion S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unlu Yatirim Holding AS
IS:UNLU
|
$31.57 Million |
|
Dawon Nexview Co., Ltd.
KQ:323350
|
$31.58 Million |
|
Muliang Viagoo Technology Inc
PINK:MULG
|
$31.58 Million |
|
Thai Wah Public Company Limited
BK:TWPC
|
$31.59 Million |
|
Centara Hotels & Resorts Leasehold Property Fund
BK:CTARAF
|
$31.56 Million |
|
MicroCloud Hologram Inc.
NASDAQ:HOLO
|
$31.55 Million |
|
Enad Global 7 AB (publ)
PINK:ENADF
|
$31.51 Million |
|
Formosa Prosonic Industries
KLSE:9172
|
$31.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mabion S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 117,776,000 to 111,442,000, a change of -6,334,000 (-5.4%).
- Net loss of 6,334,000 reduced equity.
- Other comprehensive income increased equity by 1,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-6.33 Million | -5.68% |
| Other Comprehensive Income | zł1.00K | +0.0% |
| Other Changes | zł-1.00K | -0.0% |
| Total Change | zł- | -5.38% |
Book Value vs Market Value Analysis
This analysis compares Mabion S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | zł-0.01 | zł9.40 | x |
| 2010-12-31 | zł3.15 | zł9.40 | x |
| 2011-12-31 | zł4.17 | zł9.40 | x |
| 2012-12-31 | zł342.28 | zł9.40 | x |
| 2013-12-31 | zł65.64 | zł9.40 | x |
| 2014-12-31 | zł99.20 | zł9.40 | x |
| 2015-12-31 | zł11.73 | zł9.40 | x |
| 2016-12-31 | zł0.32 | zł9.40 | x |
| 2017-12-31 | zł-4.59 | zł9.40 | x |
| 2018-12-31 | zł3.22 | zł9.40 | x |
| 2019-12-31 | zł-1.57 | zł9.40 | x |
| 2020-12-31 | zł-5.64 | zł9.40 | x |
| 2021-12-31 | zł3.43 | zł9.40 | x |
| 2022-12-31 | zł4.73 | zł9.40 | x |
| 2023-12-31 | zł7.29 | zł9.40 | x |
| 2024-12-31 | zł6.90 | zł9.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mabion S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.18%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.43x
- Recent ROE (-5.68%) is above the historical average (-100.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | zł-321.27K |
| 2010 | 2.17% | 30.86% | 0.07x | 1.08x | zł-1.70 Million |
| 2011 | -6.65% | -137.41% | 0.04x | 1.32x | zł-3.39 Million |
| 2012 | -0.12% | -239.77% | 0.00x | 2.17x | zł-184.56 Million |
| 2013 | -0.75% | -67089.66% | 0.00x | 1.45x | zł-55.95 Million |
| 2014 | -0.45% | -537.69% | 0.00x | 1.48x | zł-104.25 Million |
| 2015 | -3.60% | -168.20% | 0.01x | 1.52x | zł-17.36 Million |
| 2016 | -1497.08% | 0.00% | 0.00x | 24.47x | zł-56.20 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | zł-52.47 Million |
| 2018 | -163.44% | 0.00% | 0.00x | 3.43x | zł-73.08 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | zł-62.55 Million |
| 2020 | 0.00% | -3596.73% | 0.02x | 0.00x | zł-49.45 Million |
| 2021 | 3.57% | 3.35% | 0.31x | 3.46x | zł-3.43 Million |
| 2022 | 30.31% | 14.14% | 0.88x | 2.43x | zł15.54 Million |
| 2023 | 35.04% | 27.21% | 0.73x | 1.77x | zł29.49 Million |
| 2024 | -5.68% | -9.18% | 0.43x | 1.43x | zł-17.48 Million |
Industry Comparison
This section compares Mabion S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $101,232,545
- Average return on equity (ROE) among peers: -53.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mabion S.A. (MAB) | zł70.02 Million | 0.00% | 0.72x | $31.56 Million |
| Bioceltix S.A. (BCX) | $1.91 Million | -83.78% | 0.69x | $71.31 Million |
| Bioton S.A. (BIO) | $619.64 Million | 5.47% | 0.40x | $42.39 Million |
| Captor Therapeutics S.A. (CTX) | $124.20 Million | -26.23% | 0.16x | $69.93 Million |
| Molecure S.A. (MOC) | $126.45 Million | -10.71% | 0.09x | $21.11 Million |
| Nanogroup SA (NNG) | $8.37 Million | -119.60% | 1.43x | $12.30 Million |
| Pharmena S.A. (PHR) | $8.98 Million | -45.66% | 0.29x | $2.62 Million |
| PolTREG S.A. (PTG) | $12.83 Million | -6.84% | 0.27x | $16.72 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $7.21 Million | -65.22% | 2.02x | $2.90 Million |
| Ryvu Therapeutics SA (RVU) | $1.50 Million | -131.36% | 5.84x | $100.54 Million |